Bristol Myers dodges one $6.4B Celgene buyout CVR suit, but the battle is far from over

Did Bristol Myers Squibb deliberately drag its feet with Breyanzi’s FDA application to avoid paying former Celgene shareholders $6.4 billion? A federal judge found no proof of that intent.